MSI Financial Services’s Celldex Therapeutics CLDX Stock Holding History

MSI Financial Services’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1K	Hold	14	–	–	﹤0.01%	3632
2016 Q3	$1K	Sell	14 -9	-39%	-$560	﹤0.01%	3657
2016 Q2	$2K	Sell	23 -17	-43%	-$1.08K	﹤0.01%	3479
2016 Q1	$2K	Sell	40 -20	-33%	-$2.25K	﹤0.01%	3498
2015 Q4	$14K	Hold	60	–	–	﹤0.01%	2504
2015 Q3	$10K	Buy	60 +20	+50%	+$5.66K	﹤0.01%	2066
2015 Q2	$15K	Buy	+40	New	+$15.9K	﹤0.01%	1914

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MSI Financial Services's CLDX Position: Q4 2016 in Review

MSI Financial Services held its Celldex Therapeutics (CLDX) position steady in Q4 2016 at 14 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #3632.

MSI Financial Services first reported a position in CLDX in Q2 2015 and has held it in 7 quarters since. The position peaked at $15K in Q2 2015. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

MSI Financial Services held 14 shares of Celldex Therapeutics worth $1K as of Q4 2016.
MSI Financial Services left its Celldex Therapeutics share count unchanged in Q4 2016.
Celldex Therapeutics made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #3632 holding.
MSI Financial Services first reported a position in Celldex Therapeutics in Q2 2015 and has held it in 7 quarters since.
MSI Financial Services's Celldex Therapeutics position peaked at $15K in Q2 2015.
140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.